Dos Santos Rocha André, Peták Ferenc, Carvalho Tânia, Habre Walid, Balogh Adam L
Unit for Anaesthesiological Investigations, Department of Acute Medicine, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland.
Department of Medical Physics and Informatics, University of Szeged, Szeged, Hungary.
J Appl Physiol (1985). 2022 Apr 1;132(4):915-924. doi: 10.1152/japplphysiol.00670.2021. Epub 2022 Feb 24.
Positive pressure ventilation exerts an increased stress and strain in the presence of pulmonary fibrosis. Thus, ventilation strategies that avoid high pressures while maintaining lung aeration are of paramount importance. Although physiologically variable ventilation (PVV) has proven beneficial in various models of pulmonary disease, its potential advantages in pulmonary fibrosis have not been investigated. Therefore, we assessed the benefit of PVV over conventional pressure-controlled ventilation (PCV) in a model of pulmonary fibrosis. Lung fibrosis was induced with intratracheal bleomycin in rabbits. Fifty days later, the animals were randomized to receive 6 h of either PCV ( = 10) or PVV ( = 11). The PVV pattern was prerecorded in spontaneously breathing, healthy rabbits. Respiratory mechanics and gas exchange were assessed hourly; end-expiratory lung volume and intrapulmonary shunt fraction were measured at and . Histological and cellular analyses were performed. Fifty days after bleomycin treatment, the rabbits presented elevated specific airway resistance [69 ± 26% (mean ± 95% confidence interval)], specific tissue damping (38 ± 15%), and specific elastance (47 ± 16%) along with histological evidence of fibrosis. Six hours of PCV led to increased respiratory airway resistance (Raw, 111 ± 30%), tissue damping (G, 36 ± 13%) and elastance (H, 58 ± 14%), and decreased end-expiratory lung volume (EELV, -26 ± 7%) and oxygenation ([Formula: see text]/[Formula: see text], -14 ± 5%). The time-matched changes in the PVV group were significantly lower for G (22 ± 9%), H (41 ± 6%), EELV (-13 ± 6%), and [Formula: see text]/[Formula: see text] ratio (-3 ± 5%, < 0.05 for all). There was no difference in histopathology between the ventilation modes. Thus, prolonged application of PVV prevented the deterioration of gas exchange by reducing atelectasis development in bleomycin-induced lung fibrosis. The superposition of physiological breathing variability onto a conventional pressure signal during prolonged mechanical ventilation prevents atelectasis development in bleomycin-induced lung fibrosis. This advantage is evidenced by reduced deterioration in tissue mechanics, end-expiratory lung volume, ventilation homogeneity, and gas exchange.
在存在肺纤维化的情况下,正压通气会增加应力和应变。因此,在维持肺通气的同时避免高压的通气策略至关重要。尽管生理可变通气(PVV)已在多种肺部疾病模型中被证明有益,但其在肺纤维化中的潜在优势尚未得到研究。因此,我们在肺纤维化模型中评估了PVV相较于传统压力控制通气(PCV)的益处。通过气管内注射博来霉素诱导家兔肺纤维化。50天后,将动物随机分为两组,分别接受6小时的PCV(n = 10)或PVV(n = 11)。PVV模式预先记录于自主呼吸的健康家兔。每小时评估呼吸力学和气体交换;在0小时和6小时测量呼气末肺容积和肺内分流分数。进行组织学和细胞分析。博来霉素治疗50天后,家兔出现特异性气道阻力升高[69±26%(平均值±95%置信区间)]、特异性组织阻尼(38±15%)和特异性弹性(47±16%),同时伴有纤维化的组织学证据。6小时的PCV导致呼吸道阻力(Raw)增加(111±30%)、组织阻尼(G)增加(36±13%)和弹性(H)增加(58±14%),呼气末肺容积(EELV)降低(-26±7%)以及氧合([公式:见正文]/[公式:见正文])降低(-14±5%)。PVV组在时间匹配的变化方面,G(22±9%)、H(41±6%)、EELV(-13±6%)和[公式:见正文]/[公式:见正文]比值(-3±5%,所有P < 0.05)显著更低。通气模式之间的组织病理学无差异。因此,长时间应用PVV通过减少博来霉素诱导的肺纤维化中肺不张的发生,防止了气体交换的恶化。在长时间机械通气期间,将生理呼吸变异性叠加到传统压力信号上可防止博来霉素诱导的肺纤维化中肺不张的发生。组织力学、呼气末肺容积、通气均匀性和气体交换的恶化减轻证明了这一优势。